RT Journal Article
SR Electronic
A1 Summers, Jaye
T1 REFLEXION Trial
JF MD Conference Express
YR 2015
FD SAGE Publications
VO 15
IS 9
SP 14
OP 15
DO 10.1177/1559897715588491
UL http://mdc.sagepub.com/content/15/9/14.2.abstract
AB Many who experience a first demyelinating clinical event will convert to clinically definite multiple sclerosis. Data from the REFLEX and REFLEXION trials suggest that patients who receive early treatment with interferon beta 1-a will convert to multiple sclerosis later than patients who took placebo prior to receiving interferon beta 1-a.